New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation

Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol

(2019) Stefano Spolitu et al.   CIRCULATION RESEARCH

Metformin in 2019

(2019) James Flory et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality

(2019) Marianne Benn et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy

(2019) Rosina Pryor et al.   CELL

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

(2019) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects

(2019) Marja-Riitta Taskinen et al.   Journal of Clinical Lipidology

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial

(2018) Antonio J. Vallejo-Vaz et al.   CIRCULATION

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population

(2018) Wen Guo et al.   Lipids in Health and Disease

Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo

(2018) Anila K. Madiraju et al.   NATURE MEDICINE

Targeting hepatic pyruvate dehydrogenase kinases restores insulin signaling and mitigates ChREBP-mediated lipogenesis in diet-induced obese mice

(2018) Cheng-Yang Wu et al.   Molecular Metabolism

Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase

(2018) Roger W. Hunter et al.   NATURE MEDICINE

The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption

(2018) Günther Silbernagel et al.   JOURNAL OF LIPID RESEARCH

Inhibiting PCSK9 — biology beyond LDL control

(2018) Robert M. Stoekenbroek et al.   Nature Reviews Endocrinology

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

(2017) Brian A Ference et al.   EUROPEAN HEART JOURNAL

Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity

(2017) Deqiang Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

(2017) Marc S Sabatine et al.   Lancet Diabetes & Endocrinology

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

(2017) John R Petrie et al.   Lancet Diabetes & Endocrinology

Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

(2016) R-R Wu et al.   MOLECULAR PSYCHIATRY

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance

(2015) Ji Miao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

(2015) Joseph L. Goldstein et al.   CELL

Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes

(2015) Tao Xu et al.   DIABETES CARE

Genome-Wide Analysis of ChREBP Binding Sites on Male Mouse Liver and White Adipose Chromatin

(2015) Naravat Poungvarin et al.   ENDOCRINOLOGY

Metabolic abnormalities in Williams–Beuren syndrome

(2015) María Gabriela Palacios-Verdú et al.   JOURNAL OF MEDICAL GENETICS

Metformin: From Mechanisms of Action to Therapies

(2014) Marc Foretz et al.   Cell Metabolism

Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms

(2014) Shirya Rashid et al.   CIRCULATION

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

The effect of insulin on circulating PCSK9 in postmenopausal obese women

(2014) Zuhier Awan et al.   CLINICAL BIOCHEMISTRY

FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression

(2013) Rongya Tao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

(2013) Bertrand Cariou et al.   Nutrition & Metabolism

Novel insights into ChREBP regulation and function

(2013) Gaëlle Filhoulaud et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice

(2012) Ding Ai et al.   JOURNAL OF CLINICAL INVESTIGATION

Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes

(2012) Luke J. Engelking et al.   JOURNAL OF LIPID RESEARCH

A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism

(2012) Mark A. Herman et al.   NATURE

Hepatic FoxO1 Integrates Glucose Utilization and Lipid Synthesis through Regulation of Chrebp O-Glycosylation

(2012) Yukari Ido-Kitamura et al.   PLoS One

Insulin Resistance, Hyperglycemia, and Atherosclerosis

(2011) Karin E. Bornfeldt et al.   Cell Metabolism

O-GlcNAcylation Increases ChREBP Protein Content and Transcriptional Activity in the Liver

(2011) C. Guinez et al.   DIABETES

Inhibition of Gluconeogenic Genes by Calcium-regulated Heat-stable Protein 1 via Repression of Peroxisome Proliferator-activated Receptor α

(2011) Yanbo Fan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Williams–Beuren Syndrome

(2010) Barbara R. Pober   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study

(2009) Sarah Rosner Preis et al.   CIRCULATION

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine

(2009) Hai Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Selective versus Total Insulin Resistance: A Pathogenic Paradox

(2008) Michael S. Brown et al.   Cell Metabolism

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9

(2008) Sanae Kourimate et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

(2008) Cristen J Willer et al.   NATURE GENETICS

Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides

(2008) Jaspal S Kooner et al.   NATURE GENETICS